tellus bioventures

Venture Capital

12/19/24 Vittoria Biotherapeutics, a clinical-stage immunotherapy company specializing in the development of innovative cell therapies for hard-to-treat diseases, today announced that in November, the first patient was dosed in its Phase 1 clinical trial of VIPER-101. VIPER-101 is an enabled auto…